Shots:

• The US FDA has approved Cytalux for adult patients with ovarian cancer as an adjunct treatment for intraoperative identification of malignant lesions
• Cytalux is the first targeted fluorescent imaging agent that irradiates ovarian cancer intraoperatively & allows to detect of more cancer for removal
• The therapy received Priority Review, FTD, and ODD from the US FDA.  Additionally, Cytalux is being investigated in lung cancer in a P-II trial which is under FT designation

Ref: PR Newswire | Image: On Target Laboratorie